KR19990022712A - ａＰＬ 면역반응성 펩티드, 그것의 콘주게이트 및 ａＰＬ항체-매개병변의 치료방법 - Google Patents

ａＰＬ 면역반응성 펩티드, 그것의 콘주게이트 및 ａＰＬ항체-매개병변의 치료방법

Info

Publication number
KR19990022712A
KR19990022712A KR1019970709154A KR19970709154A KR19990022712A KR 19990022712 A KR19990022712 A KR 19990022712A KR 1019970709154 A KR1019970709154 A KR 1019970709154A KR 19970709154 A KR19970709154 A KR 19970709154A KR 19990022712 A KR19990022712 A KR 19990022712A
Authority
KR
South Korea
Prior art keywords
apl
phage
antibody
peptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019970709154A
Other languages
English (en)
Korean (ko)
Inventor
에드워드 제스 빅토리아
데이비드 매튜 마르퀴스
데이비드 에스 존스
린 유
Original Assignee
와이즈맨 앤드류
라 졸라 파마슈티칼 컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이즈맨 앤드류, 라 졸라 파마슈티칼 컴파니 filed Critical 와이즈맨 앤드류
Publication of KR19990022712A publication Critical patent/KR19990022712A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019970709154A 1995-06-07 1996-06-06 ａＰＬ 면역반응성 펩티드, 그것의 콘주게이트 및 ａＰＬ항체-매개병변의 치료방법 Ceased KR19990022712A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/482651 1995-06-07
US08/482,651 US5874409A (en) 1995-06-07 1995-06-07 APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

Publications (1)

Publication Number Publication Date
KR19990022712A true KR19990022712A (ko) 1999-03-25

Family

ID=23916889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970709154A Ceased KR19990022712A (ko) 1995-06-07 1996-06-06 ａＰＬ 면역반응성 펩티드, 그것의 콘주게이트 및 ａＰＬ항체-매개병변의 치료방법

Country Status (8)

Country Link
US (2) US5874409A (https=)
EP (1) EP0833648A4 (https=)
JP (1) JPH11507822A (https=)
KR (1) KR19990022712A (https=)
CN (1) CN1326557C (https=)
AU (1) AU711192B2 (https=)
CA (1) CA2223687A1 (https=)
WO (1) WO1996040197A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
KR20000016414A (ko) * 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
KR20020022691A (ko) * 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
AUPQ272699A0 (en) * 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
HK1045944A1 (zh) * 1999-11-28 2002-12-20 La Jolla Pharmaceutical Company 基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) * 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
CA2418006A1 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
US7319012B2 (en) * 2001-05-30 2008-01-15 Gene Therapy Systems, Inc. Protein arrays and methods and systems for producing the same
CA2451974C (en) 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
CA2467633C (en) * 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
WO2003048729A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
AU2002357779A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
NZ538628A (en) 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
US9062392B2 (en) * 2003-12-30 2015-06-23 Intel Corporation Methods for isolating a peptide methods for identifying a peptide
JP2008514187A (ja) 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
US20080118487A1 (en) * 2004-09-30 2008-05-22 Orico Limited Myostatin Isoform
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US8309068B2 (en) * 2006-08-03 2012-11-13 Myostin Therapeutics Pty Ltd. Isolated polypeptides and methods of improving muscle strength
WO2009052148A1 (en) * 2007-10-15 2009-04-23 California Institute Of Technology Functionalized polymers using protected thiols
CA2703931C (en) 2007-10-26 2016-08-16 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
CN105353137A (zh) * 2015-12-10 2016-02-24 中国农业科学院饲料研究所 一种快速检测色素苏丹红的方法
US12202858B2 (en) 2018-10-10 2025-01-21 Kagoshima University Solid-phase carrier including IgG-binding peptide, and IgG separation method
WO2022197295A1 (en) * 2021-03-17 2022-09-22 Milliken & Company Polymeric colorants with reduced staining

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE134880T1 (de) 1988-04-04 1996-03-15 Lawrence A Potempa Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
EP0450099B1 (en) * 1989-10-19 1996-09-11 Yamasa Shoyu Kabushiki Kaisha Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
US5162515A (en) * 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
CA2058769C (en) * 1990-04-06 1999-03-02 Steven Anthony Krilis Methods for determining phospholipids and antibodies thereof
DK0523035T3 (da) * 1990-04-10 1995-04-18 Masur Walter Fremgangsmåde til drift af en kompressionsvarmepumpe, og kompressionsvarmepumpe
WO1992011029A1 (en) 1990-12-17 1992-07-09 The Johns Hopkins University Suppression of immune responses with oligomeric forms of antigen of controlled chemistry
US5472883A (en) * 1992-02-05 1995-12-05 Yamasa Corporation Solid phase reagent and assay method for measuring antibodies specific to antiphospholipid syndrome
EP1808183A3 (en) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
WO1995014231A1 (en) 1993-11-16 1995-05-26 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
CN1225015A (zh) * 1996-06-06 1999-08-04 拉卓拉药物公司 aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법

Also Published As

Publication number Publication date
AU6271096A (en) 1996-12-30
US6207160B1 (en) 2001-03-27
EP0833648A1 (en) 1998-04-08
EP0833648A4 (en) 1999-10-13
WO1996040197A1 (en) 1996-12-19
JPH11507822A (ja) 1999-07-13
CN1326557C (zh) 2007-07-18
CA2223687A1 (en) 1996-12-19
US5874409A (en) 1999-02-23
AU711192B2 (en) 1999-10-07
CN1192153A (zh) 1998-09-02

Similar Documents

Publication Publication Date Title
KR19990022712A (ko) ａＰＬ 면역반응성 펩티드, 그것의 콘주게이트 및 ａＰＬ항체-매개병변의 치료방법
KR20000016414A (ko) Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
WO1996040197A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
WO1997046251A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
US6858210B1 (en) Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6932970B1 (en) Peptides for the treatment and diagnosis of systemic lupus erythematosus
US6410775B1 (en) APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
RU2322260C2 (ru) Пассивная иммунизационная терапия на основе пептидов для лечения атеросклероза
JPH01502077A (ja) 原発性胆汁肝硬変自己抗原
US7074888B1 (en) Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
JPH06113881A (ja) ヒト型モノクローナル抗ペプチド抗体及びこれをコードするｄｎａ
EP1106625A1 (en) Rhesus D specific peptide sequences
US7592421B1 (en) HLA class II peptide mimics
AU2004201699A1 (en) Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same
US20060068426A1 (en) Cyclic peptides and antibodies thereof
CN1225015A (zh) aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法
MXPA00012040A (en) THERAPEUTIC AND DIAGNOSTIC DOMAIN 1&bgr;2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20010413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030728

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040629

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20041126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20030728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I